IP Library › Granted Patent US 8,911,738
Granted Patent B2
US 8,911,738 · App. 13/199,348 · Granted Dec 16, 2014

Host cell specific binding molecules capable of neutralizing viruses and uses thereof

Inventors: Mark Throsby (Utrecht, NL); Cornelis A. de Kruif (De Bilt, NL)
Assignee: Crucell Holland B.V.
C07K16/1081
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,911,738
App. No.
13/199,348
Granted
Dec 16, 2014
Kind
B2
Abstract

Provided are human binding molecules that specifically bind to a host cell protein and have virus neutralizing activity, nucleic acid molecules encoding such human binding molecules, compositions comprising the human binding molecules, and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of viral infections.

Claims (14)

1. A composition comprising a monoclonal antibody comprising a heavy and a light chain, wherein

the heavy chain comprises the CDR1 region of SEQ ID NO:12, the CDR2 region of SEQ ID NO:13, and the CDR3 region of SEQ ID NO:6; and

the light chain comprises:

the CDR1 region of SEQ ID NO:14, the CDR2 region of SEQ ID NO:15, and the CDR3 region of SEQ ID NO:16,

or the sequence of SEQ ID NO:74.

2. The composition of claim 1 further comprising at least one tag.

3. A nucleic acid molecule encoding a monoclonal antibody comprising a heavy and a light chain, wherein

the heavy chain comprises the CDR1 region of SEQ ID NO:12, the CDR2 region of SEQ ID NO:13, and the CDR3 region of SEQ ID NO:6; and

the light chain comprises:

the CDR1 region of SEQ ID NO:14, the CDR2 region of SEQ ID NO:15, and the CDR3 region of SEQ ID NO:16, or

the sequence of SEQ ID NO:74.

4. The composition of claim 1 , further comprising at least one pharmaceutically acceptable excipient.

5. In a method of diagnosing and/or treating an infection caused by a flavivirus in a subject, the improvement comprising:

utilizing the composition of claim 1 in the diagnosis and/or treatment of the flavivirus infection in the subject, wherein said flavivirus is a West Nile Virus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2011
From: THROSBY, MARK; DE KRUIF, CORNELIS A.
To: CRUCELL HOLLAND B.V.
Reel/Frame 026900/0054 →
Priority Claims (4)
WO PCT/EP2005/052160 · May 12, 2005 · international
WO PCT/EP2005/052648 · Jun 8, 2005 · international
WO PCT/EP2005/052946 · Jun 23, 2005 · international
WO PCT/EP2005/054002 · Aug 15, 2005 · international
Continuity (2)
Division 11919265
Related Publication 20120076794A1 · Mar 29, 2012